Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours
Titel:
Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours
Auteur:
Soria, Jean-Charles Baselga, José Hanna, Nasser Laurie, Scott A. Bahleda, Rastislav Felip, Enriqueta Calvo, Emiliano Armand, Jean-Pierre Shepherd, Frances A. Harbison, Christopher T. Berman, David Park, Jong-Soon Zhang, Steven Vakkalagadda, Blisse Kurland, John F. Pathak, Ashutosh K. Herbst, Roy S.